JING LU

Jing Lu has worked in the biotechnology industry since 2002. JING began their career as a postdoc at M.D. Anderson Cancer Center, where they developed a co-culture system in a 3D model to evaluate the interplay of tumor cells with the microenvironment. JING then became a Ph.D. Candidate at the same institution, where they established the role of Epithelial-Mesenchymal Transition in promoting Her2-postive Ductal Carcinoma In Situ to invasive breast cancer. JING then moved to Novartis as a Presidential Postdoc Fellow in 2010. In 2013, they joined Arvinas. Inc as a Senior Research Scientist and Project Leader in utilizing the novel PROTAC platform to develop degraders of oncology targets. In 2015, they moved to IGNYTA, Inc. as a Senior Research Scientist. Finally, in 2016, they joined IDEAYA Biosciences as a Principal Scientist and, in 2018, they became the Director at NiKang Therapeutics Inc.

Jing Lu obtained a Bachelor's degree from Nankai University, followed by a Master's degree in Biochemistry and Molecular Biology from the same university in 2002. JING then went on to receive a Doctor of Philosophy (Ph.D.) in Oncology and Cancer Biology from The University of Texas M.D. Anderson Cancer Center in 2008.